Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol

Claudia Rutherford, Madeleine T King, David P Smith, Daniel Sj Costa, Margaret-Ann Tait, Manish I Patel, NMIBC-SI Working Group, Claudia Rutherford, Madeleine T King, David P Smith, Daniel Sj Costa, Margaret-Ann Tait, Manish I Patel, NMIBC-SI Working Group

Abstract

Background: Nonmuscle invasive bladder cancer (NMIBC) is a chronic condition requiring intensive follow-up, repeated endoscopic examinations, tumor resections, and intravesical treatments that can occur every 3 months for life. In this clinical context, patient-reported outcomes (PROs) are a critical concern for patients and their managing clinicians. PROs have enormous potential to be integral to treatment assessment and recommendations for NMIBC; however, current PRO measures are inadequate for NMIBC because they lack key NMIBC-specific symptoms and side effects associated with contemporary treatments.

Objective: The overarching aim of this study was to develop and evaluate a patient-reported symptom index (SI) for individuals with NMIBC (the NMIBC-SI) that is acceptable to patients; reliable, valid, and responsive to differences between contemporary treatments for NMIBC; and fit for purpose as an endpoint in clinical trials.

Methods: The NMIBC-SI will be evaluated in 2 field tests across a total of 3 years. Field test 1 is a cross-sectional study design involving 225 adult NMIBC patients recruited while undergoing active treatment or those who completed final treatment within the past week. Data collected include patient demographics, clinical features of the tumor, risk category, treatment type, comorbidity, and PROs. Field test 2 is a prospective longitudinal study involving 225 newly diagnosed NMIBC-SI patients. Clinical data and patient-completed questionnaires will be collected at 4 time points during treatment: before tumor resection, 1 week after resection, end-of-induction intravesical therapy, and 1-year follow-up. Standard psychometric tests will be performed to assess the reliability, validity, responsiveness, and clinical utility of the NMIBC-SI.

Results: Participant recruitment to field test 1 commenced in February 2017. Recruitment for field test 2 is planned to commence in January 2018. Final results are expected to be published in 2019. The NMIBC-SI will be freely available for use via registration.

Conclusions: This study protocol contains detailed methods that will be used across multiple international sites. Phase 2 in the development of the NMIBC-SI will enable a comprehensive evaluation of its reliability, validity, and responsiveness to ensure that the NMIBC-SI is fit for purpose in clinical research and provides an evidence base for the ongoing improvement of future therapies for NMIBC.

Trial registration: ClinicalTrials.gov NCT03091764; https://ichgcp.net/clinical-trials-registry/NCT03091764" title="See in ClinicalTrials.gov">NCT03091764 (Archived by WebCite at http://www.webcitation.org/6umBhQeNX).

Keywords: bladder cancer; cancer; patient reported outcome measures; quality of life; surveys and questionnaires.

Conflict of interest statement

Conflicts of Interest: None declared.

©Claudia Rutherford, Madeleine T King, David P Smith, Daniel SJ Costa, Margaret-Ann Tait, Manish I Patel, NMIBC-SI Working Group. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 08.11.2017.

Figures

Figure 1
Figure 1
Development and evaluation of the symptom index for individuals with nonmuscle invasive bladder cancer.

References

    1. Cheluvappa R, Smith DP, Cerimagic S, Patel MI. A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int Urol Nephrol. 2014 Jul;46(7):1351–60. doi: 10.1007/s11255-014-0643-z.
    1. . 2014. [2017-10-27]. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 .
    1. Australian Institute of Health and Welfare (AIHW) Webarchive.nla. 2014. [2017-10-26]. Summary pages for selected cancers 2014
    1. Australian Institute of Health and Welfare (AIHW) Aihw. Canberra: AIHW; 2014. Australian cancer incidence and mortality (ACIM) books .
    1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun;27(3):289–93. doi: 10.1007/s00345-009-0383-3.
    1. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M, European Association of Urology EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013 Oct;64(4):639–53. doi: 10.1016/j.eururo.2013.06.003.
    1. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012 Feb;4(1):13–32. doi: 10.1177/1756287211431976.
    1. Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Simon J, Schulman CC. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol. 2000 Apr;37(4):470–7.
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315–30.
    1. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000 Apr;163(4):1124–9.
    1. Resources.crfhealth. 2009. [2017-10-30]. Guidance for Industry: patient reported outcome measures: use in medical product development to support labeling claims .
    1. Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E, European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group Health related quality of life outcomes in cancer clinical trials. Eur J Cancer. 2005 Aug;41(12):1697–709. doi: 10.1016/j.ejca.2005.05.007.
    1. Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY, Hess R, Miller DM, Reeve BB, Santana M. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012 Oct;21(8):1305–14. doi: 10.1007/s11136-011-0054-x.
    1. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57(5):278–300. doi: 10.3322/CA.57.5.278. doi: 10.3322/CA.57.5.278.
    1. Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC) Acta Oncol. 2014 May;53(5):654–61. doi: 10.3109/0284186X.2013.864050.
    1. Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL, Espinas JA, Germa JR. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. Br Med J. 2001 Apr 7;322(7290):826.
    1. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, O'Neill R, Kennedy DL. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10 Suppl 2:S125–37. doi: 10.1111/j.1524-4733.2007.00275.x.
    1. Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010 Feb;4(1):56–64.
    1. Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003 Sep;12(6):675–88.
    1. Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD, Fayers P. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol. 2014 Dec;66(6):1148–56. doi: 10.1016/j.eururo.2014.02.034.
    1. Rutherford C, Costa DS, King MT, Smith DP, Patel MI. A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. Support Care Cancer. 2017 Apr 27;25(10):3095–102. doi: 10.1007/s00520-017-3717-5.
    1. Johnson C, Aaronson N, Blazeby JM, Bottomley A, Fayers P, Koller M, Kulis D, Ramage J, Sprangers M, Velikova G, Young T. . Brussels: EORTC Quality of Life Group; 2011. Apr, [2017-10-27]. EORTC quality of life group guidelines for developing questionnaire modules .
    1. Streiner DL, Norman GR, Cairney J. Health Measurement Scales: A Practical Guide to Their Development and Use. Oxford: Oxford University Press; 2015.
    1. Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999 Mar;104(3):605–11.
    1. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest. 2002 Sep;122(3):920–9.
    1. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, Cook JC, Murray J, Prince M, Levin E, Mann A, Knapp M. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess. 2005 Mar;9(10):1–93, iii-iv.
    1. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg. 2003 Feb;37(2):410–9. doi: 10.1067/mva.2003.152.
    1. McColl E. Developing questionnaires. In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials: Methods and Practice. New York: Oxford University Press; 2005.
    1. Nunnally JC, Bernstein IH. Psychometric Theory. New York: McGraw-Hill; 1994.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
    1. Allen MJ, Yen WM. Introduction to Measurement Theory. Monterey, CA: Waveland Press; 1979.
    1. Gorecki C, Brown JM, Cano S, Lamping DL, Briggs M, Coleman S, Dealey C, McGinnis E, Nelson AE, Stubbs N, Wilson L, Nixon J. Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument. Health Qual Life Outcomes. 2013 Jun 13;11:95. doi: 10.1186/1477-7525-11-95.
    1. Fleiss J. Reliability of measurements. In: Fleiss J, editor. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons; 1986. Feb, pp. 1–32.
    1. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40(2):171–8.
    1. Cocks K, King MT, Velikova G, Martyn SM, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011 Jan 1;29(1):89–96. doi: 10.1200/JCO.2010.28.0107.
    1. King MT, Bell ML, Costa D, Butow P, Oh B. The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. J Clin Epidemiol. 2014 Jan;67(1):100–7. doi: 10.1016/j.jclinepi.2013.02.019.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–76.
    1. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171–84. doi: 10.1586/erp.11.9.
    1. Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong LY, von Maltzahn R, Cohen L, Molsen E. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report. Value Health. 2009 Jun;12(4):430–40. doi: 10.1111/j.1524-4733.2008.00471.x.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다